A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects
The purpose of this study is to evaluate the effects of SHR7280 on the pharmacokinetics of midazolam, S-warfarin, omeprazole, digoxin and rosuvastatin in healthy subjects.
Endometriosis|Uterine Fibroids|Assisted Reproduction
DRUG: SHR7280 Tablets
Maximum concentration (Cmax), 0 to anticipated 29 days.|Area under the curve from time 0 to infinity (AUC0-âˆž), 0 to anticipated 29 days.|Area under the curve from time 0 to time t (AUC0-t), 0 to anticipated 29 days.
Time to reach the maximum concentration (Tmax), 0 to anticipated 29 days.|Half-life (t1/2), 0 to anticipated 29 days.|Apparent clearance (CL/F), 0 to anticipated 29 days.|Adverse events (AEs), Baseline up to Day 29.
The purpose of this study is to evaluate the effects of SHR7280 on the pharmacokinetics of midazolam, S-warfarin, omeprazole, digoxin and rosuvastatin in healthy subjects.